Chemosensitivity Testing in Pancreatic Cancer
Author Information
Author(s): Michalski C W, Erkan M, Sauliunaite D, Giese T, Stratmann R, Sartori C, Giese N A, Friess H, Kleeff J
Primary Institution: Technische Universität München
Hypothesis
Can ex vivo chemosensitivity testing and gene expression profiling predict response to gemcitabine treatment in pancreatic cancer?
Conclusion
Ex vivo chemosensitivity testing using ATP-TCA is feasible and may predict the response to gemcitabine chemotherapy in pancreatic cancer.
Supporting Evidence
- Chemosensitivity testing can help identify patients who will benefit from specific chemotherapy.
- Patients with gemcitabine-sensitive tumors had a significantly longer time to relapse compared to those with chemoresistant tumors.
- The study used a well-established ATP-based assay to measure chemosensitivity.
Takeaway
This study shows that testing how cancer cells respond to drugs can help doctors choose the best treatment for pancreatic cancer.
Methodology
Primary pancreatic cancer cells were isolated from patients and tested for chemosensitivity using an ATP-based assay, along with gene expression analysis.
Potential Biases
Potential bias due to the small number of patients and the specific selection criteria for inclusion.
Limitations
The study had a small sample size and short follow-up period, limiting the generalizability of the results.
Participant Demographics
18 patients with resectable pancreatic adenocarcinoma, 11 men and 7 women, median age 56 years.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website